Sign up to save your podcasts
Or
Share SMARCA4 deficient tumours are vulnerable to KDM6AUTX and KDM6BJMJD3 blockade
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
SMARCA4 deficient tumours are vulnerable to KDM6AUTX and KDM6BJMJD3 blockade
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.08.07.241232v1?rss=1
Authors: Romero, O. A., Villarrubi, A., Alburquerque-Bejar, J. J., Gomez, A., Andrade, A., Trastulli, D., Pros, E., Verdura, S., Farre, L., Martin-Tejera, J. F., Llabata, P., Oaknin, A., Saigi, M., Piulats, J. M., Matias-Guiu, X., Medina, P. P., Vidal, A., Villanueva, A., Sanchez-Cespedes, M.
Abstract:
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. This is associated with impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, which confer a strong dependency on the KDM6s in the SMARCA4-mutant cells, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the hypercalcaemic type (SCCOHT) had strong anti-tumour effects. Our results highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Copy rights belong to original authors. Visit the link for more info
View all episodes
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.08.07.241232v1?rss=1
Authors: Romero, O. A., Villarrubi, A., Alburquerque-Bejar, J. J., Gomez, A., Andrade, A., Trastulli, D., Pros, E., Verdura, S., Farre, L., Martin-Tejera, J. F., Llabata, P., Oaknin, A., Saigi, M., Piulats, J. M., Matias-Guiu, X., Medina, P. P., Vidal, A., Villanueva, A., Sanchez-Cespedes, M.
Abstract:
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. This is associated with impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, which confer a strong dependency on the KDM6s in the SMARCA4-mutant cells, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the hypercalcaemic type (SCCOHT) had strong anti-tumour effects. Our results highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Copy rights belong to original authors. Visit the link for more info